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Protein-cleavageExpression of the cellular prion protein (PrPC) is crucial for the development of prion diseases. Resistance to
prion diseases can result from reduced availability of the prion protein or from amino acid changes in the
prion protein sequence. We propose here that increased production of a natural PrP α-cleavage fragment, C1,
is also associated with resistance to disease. We show, in brain tissue, that ARR homozygous sheep, associated
with resistance to disease, produced PrPC comprised of 25% more C1 fragment than PrPC from the disease-
susceptible ARQ homozygous and highly susceptible VRQ homozygous animals. Only the C1 fragment derived
from the ARR allele inhibits in-vitro ﬁbrillisation of other allelic PrPC variants. We propose that the increased
α-cleavage of ovine ARR PrPC contributes to a dominant negative effect of this polymorphism on disease suscep-
tibility. Furthermore, the signiﬁcant reduction in PrPC β-cleavage product C2 in sheep of the ARR/ARR genotype
compared to ARQ/ARQ and VRQ/VRQ genotypes,may add to the complexity of genetic determinants of prion dis-
ease susceptibility.
Crown Copyright © 2013 Published by Elsevier B.V. All rights reserved.1. Introduction
The prion protein, PrPC, is encoded by the PRNP gene and is ex-
pressed at high levels in the central nervous system (CNS) and to a lesser
degree in peripheral tissues in all mammalian species. The biological
function of PrPC is not clear, but roles in promoting cell survival, signalervous system; CJD, Creutzfeldt–
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13 Published by Elsevier B.V. All rigtransduction and alleviating oxidative stress have been suggested
[1–3]. PrPC is essential for the pathogenesis of a group of disorders called
prion diseases, also known as transmissible spongiform encepha-
lopathies (TSEs). TSEs are fatal, neurodegenerative protein-misfolding
diseases caused by unconventional infectious agents, often referred to
as prions [4,5]. Naturally occurring prion diseases are Creutzfeldt–
Jakob disease (CJD) in man, chronic wasting disease (CWD) in deer, bo-
vine spongiform encephalopathy (BSE) in cattle and scrapie in sheep. A
marker of prion disease infection is the slow accumulation of a
protease-resistant isoform of the prion protein, designated PrPSc, in the
CNS and the peripheral lymphoid system [6]. PrPSc is converted from
PrPC by a seeded polymerisation mechanism leading to a range of mor-
phologically different aggregates, ranging from ﬁbrils to diffuse amyloid
plaques [7]. The process can bemimicked in vitro, whereby recombinant
PrPC can be induced to transit from a soluble alpha-helical state into
insoluble, highly ordered amyloid ﬁbrils by a nucleation-dependent
mechanism [8]. Most mammalian species exhibit PRNP gene polymor-
phisms which encode PrPC protein sequence variants and several
of these have been shown to modulate susceptibility, incubation period
or pathology of prion diseases [9]. One of the best described genetic
associations between PRNP gene polymorphisms (PrPC variants) and
priondiseases applies to sheep scrapie. Although the genetic determinantshts reserved.
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are highly complex, involvingmore than ten polymorphic positions, three
substitutions of major importance are in codons 136, 154 and 171. Ovine
PrPC variants are therefore described by the amino acid expressed at
these codons, such as A136R154R171 (ARR), ARQ, VRQ etc. [10–12]. It is
still a matter of debate as to exactly how PrPC amino acid substitutions
cause differences in disease susceptibility and pathogenesis. The efﬁciency
of in vitro conversion of PrPC to PrPSc has been shown to vary for different
PrPC variants [13–15] and it has been suggested that this variation is linked
to differential protein stability [14], but it is likely that in vivo additional
factors contribute to disease phenotype differences [16,17].
Ovine PrPC is expressed in brain as di- (33–35 kDa), mono-
(30–32 kDa) or un-glycosylated (27 kDa) protein in variable ratios.
Cellular processing of PrPC involves two well-documented proteolytic
cleavage events. For ovine PrPC, α-cleavage of the peptide-bond be-
tween His114 and Val115 [18,19] creates two polypeptides, of which C1
is the C-terminal fragment that resides alongside full length PrPC on
the cell membrane [20]. C1 also appears in di- (25–27 kDa) mono-
(21–23 kDa) and un-glycosylated (17 kDa) forms [21–23]. The majori-
ty of the corresponding N-terminal, 9 kDa N1 fragment is released from
the cell by shedding [24]. The products of α-cleavage of PrPC have been
observed in the brains of a variety ofmammalswith diverse susceptibil-
ity to TSE diseases [20–22,25–27]. An alternative β-cleavage, at Gly92 of
ovine PrPC, generates the fragments C2 and N2, but occurs at a much
lower level in healthy animals than α-cleavage and appears to be a re-
sponse to oxidative stress [28]. It is a long held view that prion disease
incubation periods are correlated with the amount of PrPC. This has
been demonstrated in various transgenic mouse models in which incu-
bation periods of experimentally induced prion diseases are inversely
correlated with the PrPC protein expression [29,30]. However, often in
these studies the levels of full-length PrPC and its proteolytic fragments
have not been differentiated. Recently it was shown conclusively that
the C1 fragment itself does not convert into a protease-resistant isoform
in scrapie challenged transgenic mice expressing only C1. Furthermore,
when the C1 fragment was co-expressed with full-length PrPC incuba-
tion periods were extended [31]. It has also been shown that cell lines
with naturally higher levels of α-cleavage show enhanced resistance
to prion infection [32]. This raises the possibility that PrPC cleavage
may control disease by either reducing the amount of full length PrPC
available for conversion or by producing different levels of the C1
fragment, which would act as inhibitory modulators of conversion. In
sheep, this control is likely to be associated with PRNP genotype. We
have found that proteolytic processing of ovine PrPC is PRNP genotype
dependent, with increased amounts of the C1 fragment and decreased
amounts of the C2 fragment in brain tissue from sheep associated
with resistance to scrapie. Furthermore, we have shown that a recombi-
nant protein comprising the C1 fragment derived from the ovine ARR
variant has the ability to inhibit or delay ﬁbrillisation of full length
PrP, a key step in the formation of disease associated amyloid.2. Material and methods
2.1. Brain tissue preparations
Sheep used in this study were obtained from The Roslin Institute
Cheviot ﬂock (formerly known as the NPU Cheviot ﬂock) [33] and
from a scrapie free ﬂock (AHVLA) (both in this paper called Roslin
sheep) or from random sampling at Norwegian abattoirs (in this
paper called Norwegian sheep). All sheep were arginine homozygous
in codon 154 (RR154). The VRQ/VRQ, VRQ/ARQ and ARQ/ARQ geno-
types are collectively referred to as QQ171, whilst the ARR/ARR geno-
type as RR171. For some Roslin sheep we retained 1 cm mid-sectional
slices from the left side of the brain, from which cores of approxi-
mately 5 mm in diameter were removed from the cortex, cerebellum,
medulla, thalamus, hypothalamus, mid brain and pons. Following postmortem, all tissues were immediately stored at −70 °C. Tissues were
manually homogenised in lysis buffer (5% NP-40 (v/v), 12.1 mM sodi-
um deoxycholate in PBS) with protease inhibitors (10 μM PMSF,
10 μMNEM or Complete Mini Tablets, Roche) to make a 10% (w/v) ho-
mogenate. The homogenatewas clariﬁed by centrifugation at 2000 rpm
at 4 °C for 10 min, the supernatant was collected, ﬂash frozen and
stored at−20 °C until further analysis.
2.2. Antibodies
Anti-PrP monoclonal antibodies BC6, JB10 and FH10 against PrP
epitopes 136–154, 216–225 and 198–207, respectively were kindly
gifted by Dr. Sandra McCutcheon, of The Roslin Institute. For immuno-
blotting, antibodies were used at the following ﬁnal concentrations in
0.5% (v/v) blocking reagent (Western blocking reagent 10%, Roche in
Tris buffered saline, pH 7.5); BC6 0.1 μg/mL, JB10 0.9 μg/mL, FH10
0.5 μg/mL, P4 (Biopharm) 0.2 μg/mL, 6H4 (Biopharm) 0.1 μg/mL,
anti-murine α-tubulin IgG1 (Fisher Scientiﬁc) 0.01 μg/mL, and horse-
radish–peroxidase-conjugated rabbit anti-mouse (Stratech, UK)
0.08 μg/mL. Bar224 (Bertin Pharma, SpiBio, France) which binds to
the globular domain of PrP was used at a concentration of 1 μg/mL,
diluted in TBS with 1% fat-free dry milk, and overnight at 4 °C.
2.3. Deglycosylation
Brain homogenate (10% w/v) was denatured at 100 °C for 10 min
and incubated with 0.125 U of peptide N-glycoside F (PNGase F kit,
New England Biolabs) for 2 h at 37 °C according to manufacturer's in-
structions. Deglycosylated protein was isolated using methanol precip-
itation and stored at−20 °C. Before immunoblotting, the protein was
pelleted by centrifugation at 10,400 g for 10 min. Prior to electrophore-
sis, samples were boiled directly in NuPAGE (Invitrogen) sample buffer
supplemented with a reducing agent (Invitrogen).
2.4. SDS-PAGE — immunoblotting
Deglycosylated protein was denatured at 70 °C for 10 min and sepa-
rated by 12% NuPAGE Bis-Tris gels (Invitrogen) or 12% Criterion gels
(BioRad). Molecular markers spanning 20–220 kDa were used for size
references (MagicMarker XP Western protein Standard, Invitrogen)
and electrophoresis was performed in an XCell SureLock tank at 150 V
for 1 h using a NuPAGE kit (Invitrogen) orwith the BioRad Criterion sys-
tem (BioRad). Proteinswere transferred onto poly(vinylidenediﬂuoride)
membranes (Millipore or GE Healthcare) at 25 V for 1 h, after which the
membraneswerewashedwith TBS (50 mMTris, 150 mMNaCl, pH 7.5).
Themembraneswere blocked using 1% (v/v) blocking solution for 1 h at
room temperature with agitation followed by incubation with anti-PrP
antibodies diluted in 0.5% (v/v) blocking solution under the same
conditions. Membranes were washed with TBST (0.1% Tween 20 in
TBS) followed by 0.5% (v/v) blocking solution. The membranes were
incubated in horseradish–peroxidase-conjugated rabbit anti-mouse
(Stratech, UK) or ALP conjugated goat-anti-mouse IgG (BioRad) diluted
at 1:10000 in 0.5% (v/v) block for 75 min. Themembranes were washed
in TBST andproteinswere visualised using activated chemiluminescence
(SuperSignal West Dura Extended Duration Substrate, Thermo Scientif-
ic) Lumi-Film chemiluminescent detection ﬁlm (Roche) or ﬂuorescence
(ALP substrate, ECF, GE Healthcare), recorded with a variable mode im-
ager (Typhoon, GE Healthcare), when secondary antibodies labelled
with ALP were used. For quantitative analysis, blots were scanned and
the net intensity of manually selected protein bands representative of
full length PrPC, C1 and C2 were measured by use of Kodak MI software.
In the case of ﬂuorescence scans, the ImageQuant Utility software (GE
Healthcare) was used. The combined signal of all bands for each sample
was taken as 100% and each band calculated as a percentage of the
total signal. For each animal deglycosylation, immunoblotting and
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was based on the average C1 value.
2.5. Production of C1 recombinant proteins
We have previously published details of full-length ovine PrP con-
structs [34]. Brieﬂy, PrP open reading frame from codons 25–233 was
inserted into a pTrcHis B vector and expressed in Escherichia coli strain
Rosetta (DE3). To produce truncated recombinant PrP proteins repre-
sentative of the C1 fragment the open reading frame between codons
115 and 234 of ovine PRNP from three genotypes (ARR/ARR, VRQ/VRQ
and ARQ/ARQ) was ampliﬁed by PCR from genomic DNA with oligonu-
cleotide primers Nde_C1F (CATCATATGGTGGCAGGAGCTGCTG) and
BamH1_C1R (AGTGGATCCTCAACTTGCCCCCCTTTG) and high ﬁdelity
Taq polymerase. The fragments were cloned into the PET 19b vector
(Invitrogen) and transformed into Escherichia coli strain BL21 (DE3).
The sequences of all plasmid constructs were conﬁrmed by sequencing
with T7 oligonucleotide (TAATACGACTCACTATAGG) on an AB3130 Ge-
netic Analyzer with the BigDye® terminator v3.1 cycle sequencing kit
(Applied Biosystems, USA). E. coli were cultured in terriﬁc broth (TB)
to an optical density of between 0.6 and 0.8 and PrP expression was in-
duced by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a
ﬁnal concentration of 1 mM. Bacterial lysis was performed using lyso-
zyme and inclusion bodies containing recombinant proteins were iso-
lated and stored at−20 °C — the full details of which are described in
Kirby et al. (2006) [34]. Inclusion bodies were solubilised in a urea
based buffer (urea 8 M, disodium hydro-phosphate 0.1 M, Tris-base
10 μM, pH8 with 2-mercaptoethanol). The full method for puriﬁcation
of these recombinant proteins has been previously published [35].
Brieﬂy, recombinant proteins were ﬁrst puriﬁed by nickel ion afﬁnity
chromatography, followed by desalting using a HiPrep desalting col-
umn. Proteins were oxidised overnight and further puriﬁed by reverse
phase HPLC chromatography. Puriﬁed protein was lyophilised and
stored at−20 °C. All protein variants were expressed and puriﬁed on
two separate occasions to ensure reproducibility of results.
2.6. Circular dichroism
Measurements of puriﬁed protein (~0.5 mg/mL) in 50 mM sodium
acetate were made using a Jasco J-710 spectropolarimeter with a path
length of 0.2 mm. Readings were collected from 260 nm to 200 nm,
with 20 scans repeated for each reading at a rate of 100 nm/min.
Observationsweremade about protein secondary structure by compar-
ison of the spectral output with proteins of known secondary structure.
2.7. Fibrillisation of recombinant C1
Fibrillisation followed a method previously published [36,37]. In
summary, lyophilised full length and C1 rPrP were reconstituted in
6 M guanidine-HCl (pH 6.0) to a concentration of 3 mg/mL. Reaction
mixtures contained 2 M guanidine-HCl, 50 mM MES, 10 mM thiourea
and 100 μg/mL PrP/C1. For assays with two proteins, each was added
to a ﬁnal concentration of 50 μg/mL. To monitor ﬁbrillisation kinetics,
Thioﬂavin (ThT) was added (10 μM). 167 μL of reaction mix was dis-
pensed into each well of a 96 well plate along with 3 Teﬂon balls
(2.381 mm in diameter, Precision Plastic Ball Company). The plate was
incubated with shaking, 900 rpm at 37 °C in a ﬂuorescent plate reader
(Fluoroskan Ascent, Thermo Scientiﬁc). ThT ﬂuorescencewas measured
every 5 min for 24 h (excitation at 444 nm, emission at 485 nm). Data
were analysed and lag times calculated as described in Graham et al.
2010 [37]. To account for background ﬂuorescence, ﬁbrillisation reac-
tions were set up in the absence of PrP protein. The number of repeat
ﬁbrillisation assays (n) was varied for each protein variant. For analysis
of ﬁbrils by other methods, separate reactions were set-upwithout ThT.
Post-ﬁbrillisation, these reactions were dialysed into 10 mM sodium
acetate and stored at 4 °C.2.8. Maturation and PK digestion of ﬁbrils
This protocol was followed directly from Breydo et al. [36]. Pro-
teins were visualised by gel electrophoresis (12% NuPAGE Bis-Tris
gel, Invitrogen) and silver staining.
2.9. Electron microscopy
Formvar coated copper grids were placed onto a 50 μL drop of ﬁbril
preparation (60 μg/mL in 10 mM sodium acetate, pH 5). After 45 s, the
grid was removed, touched to a ﬁlter paper to remove excess ﬂuid, and
then placed onto a drop of ﬁltered 2% aqueous phosphotungstic acid for
2 min. Grids were then air dried before storage and examined using a
Jeol 1200E× transmission electron microscope.
2.10. Statistical analysis
For analysis of all brain derived PrPC, the non-parametric Mann–
Whitney U test was applied. For in-vitro assays, the Student t-test
was applied.
3. Results
3.1. The quantity of PrPC C1-fragment relative to total PrPC is consistent
in different areas of ovine brain
To assess quantities of the C1 fragment in speciﬁc brain areas, we
measured levels of the PrPC C1 fragment relative to full length PrPC by
semi-quantitative analysis of Western blots using anti-PrP antibodies
BC6 (Fig. 1) or Bar224. Cortex, cerebellum, midbrain, thalamus, hypo-
thalamus, medulla, and pons were compared for ﬁve Roslin sheep two
of ARR/ARR and three of ARQ/ARQgenotypes. A representativeWestern
blot showing relative C1 levels in different brain regions of an ARQ
homozygous sheep is shown in Fig. 1A. Relative C1 levels varied con-
siderably between animals (e.g. levels of C1 in the cortex ranged from
14% to 48%), however, the ranking of percentage C1 levels between
areas within a single animal appeared consistent; therefore we nor-
malised C1 levels for all brain areas against the cortex (cortex = 1) for
each animal. Applying the non-parametric Mann–Whitney U-test, no
signiﬁcant differences in relative C1 levels were found between cortex
and cerebellum (0.98 ± 036), thalamus (1.36 ± 0.74), hypothalamus
(1.33 ± 0.84), mid brain (1.64 ± 1.36) medulla (1.09 ± 0.73) and
pons (1.17 ± 0.94). These data are summarised in Fig. 1B.
To conﬁrm that C1 levels are consistent across all brain areas in
animals out-with our ﬂock, we further tested cortex, cerebellum
and brainstem in four unrelated homozygous Norwegian sheep. C1
levels in cerebellum (0.78 ± 0.23) and brainstem (0.9 ± 0.54), rela-
tive to cortex, did not differ signiﬁcantly from the Roslin sheep
(data not shown). Overall, we found that relative C1 levels were sim-
ilar across different brain regions for individual animals but our data
suggested that relative C1 levels may vary depending on PRNP geno-
type. We therefore measured relative C1 levels as a function of PRNP
genotype.
3.2. The relative abundance of the PrPC C1 fragment in ovine cortex
varies with the PRNP genotype
We increased the number of Roslin sheep samples per genotype to
a total of 11 for ARR/ARR, 13 for ARQ/ARQ and 5 for VRQ/VRQ. These
genotypes of sheep were selected because they are associated with
varying susceptibility to classical scrapie. We focused on relative C1
levels in the cortex only, since we have shown that this area is repre-
sentative for most of the brain. In individual animals, relative levels of
the C1 fragment ranged from 14% to 77% of total PrPC. A representa-
tive Western blot of PrPC in the cortex of VRQ, ARQ and ARR homozy-
gous sheep is shown in Fig. 2(A) and illustrates the differences in C1
Fig. 1. Measurement of C1 fragment in different brain areas of the same animal by
Western blot. A: Representative Western blot of seven brain areas from an ARQ/ARQ
sheep. 10% brain homogenate was treated with PNGase F and the membrane was
probed with BC6 antibody. * Full length PrPC, **C2, and ***C1. These bands were
measured by densitometry and C1 levels were calculated as a percentage of total PrPC
for each brain area. B: Graph comparing average levels of C1 in the cortex with six
brain areas. C1 data from the six other brain areas was normalised against cortex
(cortex = 1) for each animal.
Fig. 2. Comparison of relative C1 levels in the ovine cortex of sheep with varied suscepti-
bility to scrapie. A: Representative Western blots from each genotype tested (ARR/ARR,
ARQ/ARQ and VRQ/VRQ). 10% brain homogenate was treated with PNGase F and the
membrane was probed with BC6 antibody. * Full length PrPC, **C2, and ***C1. B: Graph
showing the average C1 values as a percentage of total PrP as measured by densitometry.
Each samplewas blotted andmeasured aminimum of two times and the average for each
animal was plotted, ARR/ARR (n = 11), ARQ/ARQ (n = 13), and VRQ/VRQ (n = 5). An
overall average for each genotype was calculated and compared statistically using the
Mann–Whitney U test.
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repeated for each animal andwe calculated average C1 levelswithin ge-
notype groups. Animals of the ARR/ARR genotype – associated with re-
sistance to classical scrapie – had a mean relative C1 level of 52.6%
(SD ± 11.9) which was signiﬁcantly higher than the mean C1 level of
27.7% (SD ± 14.5) for ARQ/ARQ (p b 0.0001) and the mean C1 level
of 32.6% (SD ± 8.8) for VRQ/VRQ sheep (p ≤ 0.002). These data are
shown graphically in Fig. 2B. Since there was no signiﬁcant difference
between ARQ/ARQ and VRQ/VRQ animals (from here on designated as
QQ171, whilst ARR homozygous sheep are designated as RR171), which
are both associatedwith susceptibility to classical scrapie, we combined
data from these genotype groups.
It has previously been reported in several species that relative C1
levels in the brain were around 50% of total PrPC [20–22,25], in accor-
dance with our ARR/ARR sheep. To conﬁrm that the unexpectedly low
mean C1 level in our 18 QQ171 sheep (29.1% SD ± 13) was not speciﬁc
to these animals, we compared them to ﬁve Norwegian QQ171 sheep,
which showed a mean relative C1 level of 27.8% (SD ± 7.5). Analysis
with two additional antibodies FH10 and JB10 replicated the pattern
seenwith BC6 and Bar224making it highly unlikely that any of these re-
sults were signiﬁcantly inﬂuenced by the choice of antibody. We con-
clude that steady state levels of the C1 fragment relative to total PrPC
were 1.8 times (1.4–2.1, 95% conﬁdence interval) higher in the cortex
of RR171 homozygotes (n = 11) compared to QQ171 sheep (n = 23).3.3. Sheep of the ARR/ARR genotype typically have undetectable levels of
C2 fragment
In parallel to the C1 fragment, we measured the steady state levels
of the C2 fragment also by immunoblotting with antibody BC6. Across
sheep of all genotypes, the mean C2 level (for C2 ≠ 0) was 7.8%
(SD ± 4.8) of total PrPC, but only 11 out of 28 samples had detectable
C2 (deﬁned here as≥1% of total PrPC). A single RR171 sample out of 11
showed detectable C2, whereas in QQ171 samples the frequency was
10 out of 18. The RR171 samples were ﬁve times less likely to show
C2 fragment than QQ171 genotypes (p ≤ 0.01), but no correlation
was observed between relative levels of C1 and C2 (for C2 ≠ 0).
3.4. Recombinant C1 can form amyloid ﬁbrils in-vitro
Our data here show that all genotypes studied express some level of
C1. To further investigate genotype speciﬁc effects associated with the
folding pathways of the C1 fragment, we explored in-vitro ﬁbrillisation
assays with recombinant proteins. Five proteins were expressed, two
represent full-length ovine PrP25–233 of sequence variants ARR and
VRQ (designated as rPrPARR and rPrPVRQ), expressed in pTrcHis B/Rosetta
bacterial system. The three others represent truncated ovine PrP115–235
of sequence variants ARR, VRQ and ARQ, expressed in a PET-19b/BL21
(DE3) bacterial system, which are the equivalent of the C1 fragments
but which incorporate an N-terminal histidine tag to aid puriﬁcation
(designated as rC1ARR, rC1VRQ, and rC1ARQ). The regions of the protein
expressed are shown schematically in Fig. 3A.
As expected, the recombinant C1 proteinswere detected by immune-
blotting with the C-terminal antibody, BC6, but no reactivity was
observed towards the N-terminal antibody P4 (Fig. 3B). The purity of
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(Fig. 3C) and by mass spectrometry. Mass spectrometry revealed that
the rC1 proteins had been correctly expressed, but also indicated small
amounts of the protein that had been modiﬁed causing mass shifts
of +178 Da and +258 Da (see Supplementary Fig. S1). Such modiﬁca-
tions have been previously documented and are attributed to spontane-
ous alpha-N-6-phospho-gluconoylation of the His Tag [38]. These
modiﬁcations were slightly more abundant in the rC1ARR variant, but
since the levels of these modiﬁcations are already low and the modiﬁca-
tions are within the octa-histidine tag, they are unlikely to impact on
protein misfolding or stability. To check this we measured circular di-
chroism spectra (CD) for the three rC1 protein variants, which veriﬁed
that all exhibited a primarily alpha-helical structure, characterised by
spectra showing two minima at 222 nm and 208 nm, as shown in
Fig. 3D. Using CD analysis programs SELCON3 (CONTINLL) [39,40] it
was estimated that our rC1 peptides consisted of secondary structures
in the following proportions: rC1ARR was 28% (28%) α-helix, 21% (22%)
β-sheet and 51% (51%) random coil; rC1VRQ was 42% (38%) α-helix,
13% (18%) β-sheet and 46% (44%) random coil; and rC1ARQ was 28%
(34%) α-helix, 16% (17%) β-sheet and 58% (49%) random coil.
Using the ﬁve different PrP-derived recombinant proteins,
ﬁbrillisation assays were set up in the presence of Thioﬂavin T (ThT).
Fibril formation kinetics were measured over a 24-h period and lag
times were calculated as described in Graham et al. [37]. Fibrillisation
experiments were repeated multiple times and typical ﬁbrillisation
curves for C1 fragments are shown in Fig. 4, whilst typical curves
for the full length proteins rPrPVRQ and rPrPARR are shown in Fig. 7.
Fibrillisation of rPrPARR and rPrPVRQ showed an initial lag phase
(nucleation) followed by a rapid increase in ﬂuorescence on ﬁbril
growth (elongation) as reported previously for murine full length PrP
[41,42] and human full length PrP [43]. rPrPVRQ had an average lag
time of 5.57 h (SEM ± 0.40, n = 16) while with rPrPARR the lag time
was longer (p ≤ 0.002), averaging 8.32 h (SEM ± 0.69, n = 16).
Fibrillisation of rC1VRQ (n = 24) and rC1ARQ (n = 14) produced
curves thatwere qualitatively similar to those of the full-length variants,
with average lag times of 3.98 (SEM ± 0.34) and 3.96 (SEM ± 0.22)
hours respectively (Fig. 4). Once maximum ﬂuorescence was reached,
ThT ﬂuorescence curves tended to fall to around 50% of the maximum.
This phenomenon of reducing ﬂuorescence signal following ﬁbril
formation has previously been reported during the ﬁbrillisation of
human rPrP90–231. The reasons for it are yet to be fully explained, but
Almstedt et al. suggested that aggregation of ﬁbrils was the most likely
cause, thereby reducing the outward facing regions available for ThT
binding [43].
Compared to other rC1 proteins, rC1ARR (n = 24) showed a modi-
ﬁed ﬁbrillisation proﬁle comprising a signiﬁcantly longer lag time
(p ≤ 2.5 × 10−6), on average 11.0 h (SEM ± 1.0) (Fig. 4) and a re-
duced elongation rate after nucleation. Indeed, complete ﬁbrillisation
often did not occur within the 24 h time frame of the experiment; in
these cases the lag times could not be calculated, since this calculation
depends on maximal levels of ThT ﬂuorescence being achieved. Fig. 4
shows an example of two rC1ARR reactions, one positive and one
negative for complete ﬁbrillisation. These results indicate that rC1ARR
has a decreased ability to form amyloid ﬁbrils when compared to
other two rC1 variants.
To conﬁrm that C1 proteins were producing ﬁbrils rather than
non-ﬁbrillar, ThT-binding aggregates, we applied a ﬁbril maturation
assay originally described by Bocharova et al. [44]. Fibrils composed
of rPrP have a PK resistant core of 10–12 kDa, but by heating PrP am-
yloid ﬁbrils to 80 °C a structural change is initiated such that the
PK-resistant core is extended to 16 kDa. Protease-resistant PrP canFig. 3. Characterisation of rC1 proteins. A: Diagrammatic representation of recombinant full len
sence of the N-terminal region. B:Western blots of rC1 proteins, probed withmonoclonal antib
lane 3: rC1VRQ. rC1 was not recognised by P4 but showed binding to BC6. C: All variants of reco
conﬁrm purity. Lane 1: rPrPARR, lane 2: rPrPVRQ, lane 3: rC1ARR, lane 4: rC1ARQ, and lane 5: rC1Vbe detected by SDS-PAGE and silver staining and typical results are
shown in Fig. 5. For the full length rPrP samples, a well-deﬁned
16 kDa band is evident after maturation along with the characteristic
12 and 10 kDa fragments, consistent with previously reported results
[36,44] and conﬁrming the presence of ﬁbrils. In rC1 ﬁbrillisation re-
actions along with the three bands described above, two additional
PK-resistant fragments appeared after maturation, one of similar
size to the intact rC1 protein (~16.6 kDa) and one of ~13 kDa. The
presence of a 13 kDa band was also evident in maturation assays of
human PrP90–231 [45] and may indicate formation of disordered ag-
gregates with increased PK resistance. The 16.6 kDa band could rep-
resent an increase in core expansion or a structural change which
alters available PK digestion sites. The 16 kDa band was less intense
in rC1 ﬁbril preparations compared to rPrP preparations, suggesting
that a reduced amount of ﬁbrils may be produced in rC1 ﬁbrillisation
reactions.
To further characterise rC1 amyloid ﬁbrils, we analysed prepara-
tions by electron microscopy, as shown in Fig. 6. Fibrils were observed
in all preparations and there were no clear morphological differences
between ﬁbrils from different samples, although using this technique
it was not possible to quantify the number of ﬁbrils. Nevertheless, it is
clear that rC1 proteins all form ﬁbrils in a similar manner to rPrP, but
that ﬁbrillisation of the rC1ARR protein proceeds with an extended lag
time and reduced growth rate compared to rC1VRQ and rC1ARQ.
3.5. rC1ARR but not rC1VRQ or rC1ARQ inhibits ﬁbrillisation of other PrP
variants
In vivo, it is possible that the C1 fragment may interfere with
misfolding of full length PrPC. Depending on their PRNP genotype,
ovine cells will contain a mixture of full-length PrPC molecules and
C1 fragments with identical or different protein sequences at ratios
that vary from 4:1 to 1:1. To partially mimic this in vivo scenario,
we performed mixed ﬁbrillisation assays with both truncated and
full length recombinant proteins at different ratios. Fibrillisation reac-
tions were repeated multiple times and typical results for selected re-
action mixtures are show in Fig. 7. rPrPVRQ was mixed at a 1:1 ratio
with rC1ARR (n = 10), rC1ARQ (n = 6) or rC1VRQ (n = 10) and the
lag time of ﬁbrillisation was measured. There was no signiﬁcant
change in lag time with addition of rC1ARQ (data not shown) or
rC1VRQ compared to rPrPVRQ alone. However, rC1ARR addition signiﬁ-
cantly increased the lag time of ﬁbrillisation of rPrPVRQ from 5.57 h
(SEM ± 0.40) to 10.6 h (SEM ± 1.12) (p = 5.2 × 10−5). As ob-
served with ﬁbrillisation of rC1ARR, approximately 75% of the mixed
assays containing rC1ARR did not result in full ﬁbrillisation within
the time frame of the experiment and therefore lag times could not
be calculated in these cases. When full ﬁbrillisation was achieved,
it was evident that the elongation phase of ﬁbrillisation of rPrPVRQ
was extended and closely resembled those observed with rC1ARR
alone, with a slow ThT increase after nucleation and low maximum
ﬂuorescence.
The presence of ﬁbrils in these mixed assays was conﬁrmed using
the maturation assay, as shown in Fig. 5, which showed 10 and
12 kDa bands as described for both rPrP species alongwith a prominent
16.6 kDa band associated with C1 ﬁbrils alone after maturation. The
16 kDa bandwhichwould conﬁrm the presence of full length PrP ﬁbrils
is very faint when compared to maturation and PK digestion of full
length rPrP alone, indicating that full length PrP has not formed amyloid
ﬁbrils but this mixed reaction favours the production of C1 ﬁbrils.
Reactions at a 4:1 rPrPVRQ:rC1ARR ratiowere also performed (n = 7),
in which average lag time for ﬁbrillisation of rPrPVRQ was increased togth and truncated C1 protein. C1was expressed with His-Tag to aid puriﬁcation in the ab-
odies P4 (epitope 89–104) and BC6 (epitope 146–154). Lane 1: rC1ARR; lane 2: rC1ARQ, and
mbinant protein expressed were separated by SDS-PAGE and stained with Instant Blue to
RQ. D: Circular dichroism analysis of three C1 variants to assess secondary structure.
Fig. 4. Kinetics of rC1 ﬁbrillisation measured by ThT ﬂuorescence. Typical ﬁbrillisation
curves for each rC1 variant. rC1ARQ and rC1VRQ have short lag times followed by a rapid
elongation phase. rC1ARR often did not reach ﬁbrillisation within the time frame of the
experiment, described as negative for ﬁbrillisation (rC1ARR-ve).
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inhibited to less of an extent compared to the 1:1 reactions. The rate of
elongation and maximum ﬂuorescence were lower than seen with full
length protein alone,with 3 out of 7 repeats failing toﬁbrillise fullywith-
in the time frame of the experiment (Fig. 7).
We then mixed rPrPARR with all three variants of C1 at a 1:1 ratio.
Addition of rC1ARR to rPrPARR (n = 10) increased the average lag time
only marginally from 8.3 (SEM ± 0.69) to 9.0 (SEM ± 0.41), but re-
duced the rate of ﬁbril elongation dramatically, as illustrated in Fig. 7.
In contrast, addition of rC1VRQ or rC1ARQ (data not shown) to rPrPARR
shortened the lag time of ﬁbrillisation. The early ThT ﬂuorescence
increase may represent C1 ﬁbrillisation and mask the slightly later
ﬁbrillisation of rPrPARR or the addition of these C1 variantsmay increase
the rate of nucleation and elongation of rPrPARR. Further evidence to
support the second of these hypotheses is the observation, in some
mixed reactions, of two peaks of ﬂuorescence, illustrated in the
rPrPVRQ + rC1VRQ ﬁbrillisation curve in Fig. 7. In these cases, curves of
best ﬁt could not be produced and lag times were not calculated.
We propose that the two ﬂuorescence maximamay represent sep-
arate ﬁbrillisation mechanisms of the two protein variants, however,
at this point we have no direct evidence of this. Across all our
ﬁbrillisation reactions, we calculated lag times, for those reactions
that produced a maximum of ThT ﬂuorescence, and averaged these.
The results are shown graphically in Fig. 8, from which it is clear
that the rC1ARR inhibits ﬁbrillisation of both full length rPrPARR and
rPrPVRQ whilst rC1VRQ and rC1ARQ do not inhibit ﬁbrillisation.Fig. 5.Maturation and PK digestion of PrP and C1 ﬁbrils. 0.5 μg of recombinant protein was u
followed by PK treatment (lane 3). Matured ﬁbrils (lane 3) show increased PK resistance rel
conﬁrms the presence of ﬁbrils, highlighted by the black box. In rC1 preparations, bands with
dotted box. Mixed reactions of rPrPVRQ and rC1 have a prominent band of 16.6 kDa with a4. Discussion
The susceptibility of sheep to various natural prion diseases provides
a valuable genetic model of disease resistance in which mechanisms of
protein misfolding and neurodegeneration can be studied [16,33,46].
PRNP genetics are exploited worldwide in breeding programmes to
manage the risk of scrapie outbreaks, despite a critical lack of under-
standing the underlying mechanisms that link PrPC variants to disease
resistance. By revealing a molecular basis of resistance, more effective
measures could be put in place both to restrict new prion strains from
adapting to low risk PRNP genotypes and to maintain PrPC variants
with protective potential.
A number of in vitro studies into themolecular aspects of resistance
of speciﬁc sheep genotypes to scrapie have probed the initial binding of
cellular to disease-associated prion protein prior to conversion [47,48]
or on the relative convertibility of prion protein variants [15,34]. Others
have tried to explain disease resistance by allele-speciﬁc expression
proﬁles [47,48], different protein conformations or different character-
istics of ﬁbrillisation and thermal stability [14]. Our results demonstrate
that there are higher levels of PrPCα-cleavage fragments in sheep of the
scrapie-resistant genotype ARR/ARR relative to sheep of more suscepti-
ble genotypes. The C1 fragment is produced by the action of an
unknown ‘α-secretase’ and high C1 levels in ARR/ARR sheep may
result from an increased proteolytic processing of PrPARR compared
to PrPARQ or PrPVRQ or due to differences in the half-lives of the allo-
typic C1 fragments. The formermay be explained by conformational dif-
ferences leading to increased presentation of the cleavage site for the
α-secretase or by the extended presence of PrPARR within the Golgi ap-
paratus increasing the chance of interacting with the α-secretase [49].
Setting the reason for the differences aside, the correlation between a
high C1 level and scrapie resistance is supported by similar evidence
from cell culture assays and transgenic mouse models. Lewis et al. [32]
showed that neuronal and non-neuronal cell lines with higher levels of
α-cleavage show more resistance to prion infection and concluded that
this cleavage is the most important factor in the selective vulnerability
to prions [32]. Scrapie challenges in transgenic mice expressing only C1
protein [31] showed that C1 alone does not act as a substrate for conver-
sion to PrPSc. Over-expression of C1 in the presence of full length PrPC
slowed accumulation of PrPSc and extended the incubation period of dis-
ease in these transgenic mice, supporting the view that C1 may inhibit
some unknown pathway in the conversion of PrPC to PrPSc.
Along with the possible effects of C1, the corresponding product of
α-cleavage, N1 has been shown to possess neuroprotective functions.
For example, N1 can inhibit staurosporine induced caspase-3 activation
through the p53 pathway [50] and addition of a recombinant N1 iso-
form in cultured cells also shows dose dependent neuroprotective ef-
fects [51]. Although we have not measured levels of N1 in our sheepntreated (lane 1), PK treated at a ratio of PrP:PK (lane 2), or matured by heating to 80 °C
ative to non-matured ﬁbrils. rPrP reactions show a 16 kDa band after maturation which
increased PK resistance of 16.6 kDa, 16 kDa and 13 kDa are present, highlighted by the
faint 16 kDa band, highlighted by the dashed box.
Fig. 6. Electron Microscopy of rC1 and rPrP ﬁbrils. Fibrils were produced in the absence of ThT and dialysed into sodium acetate. Fibrils were viewed on a transmission electron
microscope. Images were taken at ×5000 and ×20,000. A: rC1ARR, B: rC1ARQ, C: rC1VRQ, D: rPrPARR, and E: rPrPVRQ.
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sponding C1 fragment and it is likely, therefore, that the increased levels
of this fragment in disease-resistant animals will represent an addition-
al beneﬁt in protection against the neurodegeneration associated with
prion disease.
Our observation that relative C2 levels in ARR/ARR sheep were sig-
niﬁcantly reduced when compared to the other genotypes is surprising,
since there is little supporting evidence of an inverse correlationbetween α- and β-cleavage in healthy individuals. The small C2 per-
centage in sheep with QQ171 genotypes may represent an additional
susceptibility-enhancing factor which remains to be investigated in
more detail. Truncated recombinant PrP (90–231), representing the
C2 isoform, has a similar ability to aggregate and ﬁbrillise as full length
recombinant PrP [52].
Since PrPARR associated with prion resistance produces increased C1
levels in vivo and the presence of C1 protein reduces PrP conversion
Fig. 7. Fibrillisation of rPrP in the presence of rC1. Typical ﬁbrillisation curves for mixed reactions. Addition of C1ARR to full length PrPARR and PrPVRQ at both a 1:1 and a 4:1 ratio
extends the lag time of ﬁbrillisation, slows the rate of ThT ﬂuorescence increase and lowers maximum ﬂuorescence. These effects are reduced in experiments at a 4:1 ratio. During
mixed reactions, two peaks of ﬂuorescence were evident in some wells, illustrated in rPrPVRQ + rC1VRQ at 1:1.
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whether the C1 fragment could interferewithmisfolding of PrP.We pro-
duced various allotypes of recombinant C1 and full length PrP and
assessed their ability to form amyloid ﬁbrils in vitro. All variants had
the ability to form amyloid ﬁbrils as conﬁrmed by increases in ThT ﬂuo-
rescence duringﬁbrillisation, the presence of a 16 kDa protease-resistant
core after maturation [44] and the presence of ﬁbrillar aggregates
visualised by electron microscopy.
rC1ARR had a signiﬁcantly longer lag time of ﬁbrillisation and an al-
tered ﬁbril growth phase when compared to both other allotypic
forms of rC1 and rPrPC. Often reactions with rC1ARR would fail to
ﬁbrillise fully within the time frame of the experiment indicating
that this protein has a reduced potential to form ﬁbrils. Similarpolymorphism dependent differences have been reported with in
vitro conversion of human rPrP90–231 [53–55].
When mixed with other protein variants at a ratio of 1:1, to repre-
sent a situation similar to heterozygous brain tissue, rC1ARR inhibited
ﬁbril formation whilst rC1ARQ and rC1VRQ did not. In ﬁbrillisation reac-
tions with a rPrPC:rC1 ratio of 4:1, inhibition was observed but the in-
crease in lag time was less dramatic suggesting that the rPrP:rC1 ratio
could be an important factor if similar inhibitory mechanisms apply in
vivo.
Our ﬁndings show that rC1ARR can inhibit the initial nucleation of
amyloid ﬁbrils and slow the elongation phase of ﬁbrillisation, but it is
unclear if C1 also prevents conversion of PrPC to PrPSc. Westergard et
al. hypothesised that C1 acts as competitor for the binding of PrPC to
Fig. 8. Addition of rC1ARR increases lag time of ﬁbrillisation of other rPrP variants.
A: Graph showing average lag time for rPrPVRQ:rC1ARR, rC1ARQ, and rC1VRQ mixed
ﬁbrillisation reactions along with the frequency of reactions failing to ﬁbrillise within
the 24 h time frame of the experiment, calculated as a percentage of total reactions.
B: As described for graph A for rPrPARR:rC1ARR, rC1ARQ, and rC1VRQ mixed ﬁbrillisation
reactions.
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results by showing that rC1 can directly inhibit the formation of rPrP
amyloid ﬁbrils in the absence of PrPSc and we believe that there may
be two mechanisms explaining this inhibition. The rC1 protein may
bind to rPrP and prevent further interaction with other rPrP proteins
thereby inhibiting the formation of an initiating nucleus. Alternative-
ly, the rC1 protein may become incorporated into amyloid ﬁbrils of
rPrP, which would interfere with subsequent elongation of the ﬁbrils,
perhaps by inducing the formation of disordered aggregates. Since
the addition of rC1ARR both increases the lag time and alters the elon-
gation phase, both putative mechanisms may occur simultaneously.
In contrast to the ﬁndings by Westergard et al. in our in vitro as-
says only one out of three ovine C1 sequences had an inhibiting effect
on ﬁbril formation, indicating it is the arginine at position 171 specif-
ically which is responsible for the effects seen. Wild type, ovine C1ARQ
appeared not to affect ﬁbril formation in vitro, whereas mouse wild
type C1, which is different from sheep C1ARQ by only nine amino
acid changes — has a delaying effect on development of TSE disease
in vivo [31]. It remains to be established whether this indicates that
the inhibition mechanism for the seeded and un-seeded nucleation
or elongation is different or that the effects of C1 on prion replication
are ampliﬁed in an in-vivo situation.
The dominant negative inhibitory effect of C1may be a crucial com-
ponent in deﬁning susceptibility and incubation periods in sheep of het-
erozygous PRNP genotypes. Experimental scrapie in VRQ/ARR sheep can
lead to incubation periods twice as long as for VRQ/VRQ sheep and lon-
ger than VRQ/ARQ [9,56,57]. Furthermore, in experimental BSE,incubation periods in sheep of the ARQ/ARR genotype can be four
times as long as for ARQ/ARQ sheep [58] (Goldman et al. unpublished).
Our data indicate that the ratio of full-length rPrPC and rC1 fragment in-
ﬂuences the strength of inhibition. Based on our results the ratio be-
tween rC1ARR and rPrPVRQ should be close to equal in VRQ/ARR sheep,
whilst in ARQ/ARR sheep there should be approximately twice as
much rC1ARR than rPrPARQ, supporting the idea that C1 fragments in-
deed play a part in scrapie pathogenesis.
The ability of rC1ARR to inhibit conversion of rPrP makes it a possi-
ble therapeutic target in the treatment of prion disease. The possible
effects of C1 protein if applied exogenously or increasing the levels
of α-cleavage through manipulation of α-secretase in the in the
early stages of TSE infection may slow disease progression, and war-
rant further investigation.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.02.020.
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